Pharma

Pharma major Lupin Ltd has received final approval from the USFDA to market sodium sulfate, potassium sulfate, magnesium sulfate oral solution used in treatment of a form of cancer.

Dr Reddy's Laboratories on Thursday said it has received an unfavourable ruling in a US court regarding a patent infringement case over Aloxi.

Dr Reddy's is recalling Olanzapine tablets USP of 2.5 mg while Aurobindo is recalling Pantoprazole Sodium for Injection, 40mg per vial from the market, the notification issued by the US regulator said.

Among the key issues of concern for the US pharma sector in India are unpredictable IP environment, high tariffs and taxes on medicines among others.

Drug firm Ajanta Pharma on Thursday said the US health regulator has issued one observation for its Paithan facility in Aurangabad after the inspection.

The recall is being initiated by Sun Pharmaceutical Industries Inc for 2,71,212 bottles of bupropion hydrochloride extended-release tablets, USP (SR) in the strengths of 150 mg and 200 mg, the FDA said.

Mr Piramal curtailed his presence in healthcare after he sold erstwhile Piramal Healthcare's domestic formulations division for $3.7 billion to Abbott in 2010.

With the growth momentum hit hard by the notes ban, Nomura had earlier projected GDP growth to dip to 6.9 per cent in 2017 from 7.1 per cent in 2016, with a sharp slowdown in the first half of the current year.

In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price by 10 per cent annually.

The FDA had inspected the Kothur formulation facility between January 16-24, 2017, Natco Pharma said in a statement.

Natco Pharma said it will provide due justifications and corrective action plan within next 15 working days to the address the USFDA observations.

There were media reports saying the company has got import alert from USFDA for its Paithan unit at Aurangabad for which BSE had sought for a clarification from Ajanta Pharma.

Quoting IMS MAT September 2016 data, Lupin said, Paxil CR tablets had US sales of $127.7 million.

The transaction will be EPS (earnings per share) accretive, Zydus Cadila said in a statement.

The additional sum is derived on the basis of the value of mutual funds, cash and bank balance, tax refunds etc at the time of closing, it added.